AxoGen, Inc. Stock News

LOS ANGELES--(BUSINESS WIRE)--Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN.

Shares of Axogen plunged Monday after the FDA delayed the expected approval date for the company's nerve graft product.

ALACHUA, Fla. and TAMPA, Fla.

Axogen is compounding business capital at increasing returns which was reflected in Q2 earnings. The stock remains in a down-trend with investors compressing multiples paid on capital invested into the business. The range of potential outcomes remains broad which coincides with historical trends seen in market for this name.

Axogen (AXGN) Q2 Revenue Jumps 18%

Axogen, Inc. (NASDAQ:AXGN ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Jens Schroeder Kemp - Chief Marketing Officer Lindsey Hartley - Chief Financial Officer Michael D. Dale - President, CEO & Director Rick Ditto - Corporate Participant Conference Call Participants Caitlin Cronin - Canaccord Genuity Corp., Research Division Christopher Thomas Pasquale - Nep...

ALACHUA, Fla. and TAMPA, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management will be available for one-on-one investor meetings at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025.

ALACHUA, Fla. and TAMPA, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will report 2025 second quarter financial results on Tuesday, August 5, 2025, before the market opens. Axogen management will host an investment-community ...